60 Degrees Pharmaceuticals Surges to 466th in Trading Volume with 27.8 Million Turnover

On April 8, 2025, 60 Degrees Pharmaceuticals (SXTP) saw a significant surge in trading volume, with a turnover of 27.8 million, marking a 293.79554% increase from the previous day. This placed the stock at the 466th position in terms of trading volume for the day. The stock price of 60 Degrees Pharmaceuticals (SXTP) rose by 59.59%, marking its second consecutive day of gains, with a total increase of 62.15% over the past two days.

60 Degrees Pharmaceuticals reported its full-year 2024 earnings, revealing that while earnings per share (EPS) exceeded expectations, revenues fell short. This financial performance highlights the company's mixed results for the year, with notable achievements in certain areas but overall revenue underperformance.

The company recently announced a patent license agreement with Yale School to advance the development of Tafenoquine for the treatment and prevention of Babesiosis. This strategic partnership is aimed at leveraging the expertise and resources of both entities to accelerate the development of this critical therapeutic.

Despite facing significant losses in 2024, 60 Degrees Pharmaceuticals experienced a remarkable surge in revenue growth, particularly in the infectious disease sector. This growth underscores the company's potential for future success, despite the challenges encountered in the past year.

60 Degrees Pharmaceuticals reported a 140% increase in net product revenues for the fiscal year 2024, reaching $607.6 thousand. This substantial growth in revenue reflects the company's efforts to expand its product offerings and capture a larger share of the market.